Mechanisms involved in VPAC receptors activation and regulation: Lessons from pharmacological and mutagenesis studies

Frontiers in Endocrinology

Volumn 3, Issue OCT, 2012, Pages

  Langer, Ingrid ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Activation; Mutagenesis; Oligomerization; Regulation; Signaling; VIP; VPAC1; VPAC2

Indexed keywords

EID: 84874379410     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00129     Document Type: Review

References (69)

1. Akesson, L., Ahren, B., Edgren, G., and Degerman, E. (2005). VPAC2R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes. Endocrinology 146, 744-750.
2. Ceraudo, E., Hierso, R., Tan, Y. V., Murail, S., Rouyer-Fessard, C., Nicole, P., et al. (2012). Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction. FASEB J. 26, 2060-2071.
3. Christopoulos, A., Christopoulos, G., Morfis, M., Udawela, M., Laburthe, M., Couvineau, A., et al. (2003). Novel receptorpartners and function of receptor activity-modifying proteins. J. Biol. Chem. 278, 3293-3297.
4. Chu, A., Caldwell, J. S., and Chen, Y. A. (2010). Identificationandcharacterization of a small molecule antagonist of human VPAC(2) receptor. Mol. Pharmacol. 77, 95-101.
5. Chugunov, A. O., Simms, J., Poyner, D. R., Dehouck, Y., Rooman, M., Gilis, D., et al. (2010). Evidence that interaction between conserved residues in transmembrane helices 2, 3, and 7 are crucial for human VPAC1 receptor activation. Mol. Pharmacol. 78, 394-401.
6. Conklin, B. R., Herzmark, P., Ishida, S., Voyno-Yasenetskaya, T. A., Sun, Y., Farfel, Z., et al. (1996). Carboxylterminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation. Mol. Pharmacol. 50, 885-890.
7. Conner, A. C., Hay, D. L., Simms, J., Howitt, S. G., Schindler, M., Smith, D. M., et al. (2005). A key role for transmembrane prolines in calcitonin receptor-like receptor agonist binding and signalling: implications for family B G-protein-coupled receptors. Mol. Pharmacol. 67, 20-31.
8. Conner, A. C., Simms, J., Conner, M. T., Wootten, D. L., Wheatley, M., and Poyner, D. R. (2006). Diverse functional motifs within the three intracellular loops of the CGRP1 receptor. Biochemistry 45, 12976-12985.
9. Couvineau, A., and Laburthe, M. (2012). VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br. J. Pharmacol. 166, 42-50.
10. Couvineau, A., Lacapere, J. J., Tan, Y. V., Rouyer-Fessard, C., Nicole, P., and Laburthe, M. (2003). Identification of cytoplasmic domains of hVPAC1 receptor required for activation of adenylyl cyclase. Crucial role of two charged amino acids strictly conserved in class II G protein-coupled receptors. J. Biol. Chem. 278, 24759- 24766.
11. Cypess, A. M., Unson, C. G., Wu, C. R., and Sakmar, T. P. (1999). Two cytoplasmic loops of the glucagon receptor are required to elevate cAMP or intracellular calcium. J. Biol. Chem. 274, 19455-19464.
12. Delgado, M., Pozo, D., and Ganea, D. (2004).Thesignificanceof vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56, 249-290.
13. Dickinson, T., Mitchell, R., Robberecht, P., and Fleetwood-Walker, S. M. (1999). The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy. Neuropharmacology 38, 167-180.
14. Dickson, L., and Finlayson, K. (2009). VPAC and PAC receptors: from ligands to function. Pharmacol. Ther. 121, 294-316.
15. Frimurer, T. M., and Bywater, R. P. (1999). Structure of the integral membrane domain of the GLP1 receptor. Proteins 35, 375-386.
16. Gaudin, P., Couvineau, A., RouyerFessard, C., Maoret, J. J., and Laburthe, M. (1999). The human vasoactive intestinal Peptide/Pituitary adenylate cyclase activating peptide receptor 1 (VPAC1): constitutive activation by mutations at threonine 343.Biochem.Biophys.Res.Commun. 254, 15-20.
17. Gaudin, P., Maoret, J. J., Couvineau, A., Rouyer-Fessard, C., andLaburthe, M. (1998). Constitutive activation of the human vasoactive intestinal peptide1receptor, amemberofthe new class II family of G proteincoupled receptors. J. Biol. Chem. 273, 4990-4996.
18. Gonzalez-Rey, E., Chorny, A., and Delgado, M. (2007). Regulation of immune tolerance by antiinflammatory neuropeptides. Nat. Rev. Immunol. 7, 52-63.
19. Gutierrez-Canas, I., Juarranz, M. G., Collado, B., Rodriguez-Henche, N., Chiloeches, A., Prieto, J. C., et al. (2005). Vasoactive intestinal peptide induces neuroendocrine differentiationintheLNCaPprostatecancercell line through PKA, ERK, and PI3K. Prostate 63, 44-55.
20. Harikrishnan, L. S., Srivastava, N., Kayser, L. E., Nirschl, D. S., Kumaragurubaran, K., Roy, A., et al. (2012). Identification and optimization of small molecule antagonists of vasoactive intestinal peptide receptor-1 (VIPR1). Bioorg. Med. Chem. Lett. 22, 2287-2290.
21. Harikumar, K.G., Morfis, M.M., Lisenbee, C.S., Sexton, P.M., andMiller, L. J. (2006). Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors. Mol. Pharmacol. 69, 363-373.
22. Harmar, A. J., Fahrenkrug, J., Gozes, I., Laburthe, M., May, V., Pisegna, J. R., et al. (2012). Pharmacology andfunctionsofreceptorsforvasoactive intestinal peptide and pituitary adenylatecyclase-activatingpolypeptide: IUPHAR review 1. Br. J. Pharmacol. 166, 4-17.
23. Harmar, A. J., Sheward, W. J., Morrison, C. F., Waser, B., Gugger, M., and Reubi, J. C. (2004). Distribution of theVPAC2 receptor in peripheral tissuesofthemouse.Endocrinology 145, 1203-1210.
24. Hoare, S. R. (2005). Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov. Today 10, 417-427.
25. Huang, J., Mahavadi, S., Sriwai, W., Grider, J.R., andMurthy, K.S.(2007). Cross-regulation of VPAC(2) receptor desensitization by M(3) receptors via PKC-mediated phosphorylation of RKIPandinhibitionof GRK2.Am. J. Physiol. Gastrointest. Liver Physiol. 292, G867-G874.
26. Juarranz, M. G., Bolanos, O., GutierrezCanas, I., Lerner, E. A., Robberecht, P., Carmena, M. J., et al. (2001). Neuroendocrine differentiation of the LNCaP prostate cancer celllinemaintainstheexpressionand function of VIP and PACAP receptors. Cell. Signal. 13, 887-894.
27. King, V. M., Chahad-Ehlers, S., Shen, S., Harmar, A. J., Maywood, E. S., and Hastings, M.H. (2003). Ah VIPR transgene as a novel tool for the analysis of circadian function in the mouse suprachiasmatic nucleus. Eur. J. Neurosci. 17, 822-832.
28. Knudsen, S. M., Tams, J. W., and Fahrenkrug, J. (2001). Functional roles of conserved transmembrane prolines in the human VPAC(1) receptor. FEBS Lett. 503, 126-130.
29. Langer, I., Gaspard, N., andRobberecht, P. (2006). Pharmacological properties of Chinese hamster ovary cells coexpressing two vasoactive intestinal peptide receptors (hVPAC1 and hVPAC2). Br. J. Pharmacol. 148, 1051-1059.
30. Langer, I., Langlet, C., and Robberecht, P. (2005). Effect of inactivatingmutationsonphosphorylation and internalization of the human VPAC2 receptor. J. Mol. Endocrinol. 34, 405-414.
31. Langer, I., Perret, J., Vertongen, P., Waelbroeck, M., and Robberecht, P. (2001). Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMPin CHO cells expressing Galpha16. Cell Calcium 30, 229-234.
32. Langer, I., and Robberecht, P. (2005). Mutations in the carboxy-terminus of the third intracellular loop of the human recombinant VPAC1 receptor impair VIP-stimulated [Ca2+]i increase but not adenylate cyclase stimulation. Cell. Signal. 17, 17-24.
33. Langer, I., Vertongen, P., Perret, J., Waelbroeck, M., and Robberecht, P. (2002). A small sequence in the third intracellular loop of the VPAC(1) receptorisresponsibleforitsefficient couplingtothecalciumeffector. Mol. Endocrinol. 16, 1089-1096.
34. Langer, I., Vertongen, P., Perret, J., Waelbroeck, M., and Robberecht, P. (2003). Lysine 195 and aspartate 196 in the first extracellular loop of the VPAC1 receptor are essential for high affinitybindingof agonistsbutnotof antagonists. Neuropharmacology 44, 125-131.
35. Langlet, C., Gaspard, N., Nachtergael, I., Robberecht, P., and Langer, I. (2004). Comparative efficacy of VIP and analogs on activation and internalizationoftherecombinantVPAC2 receptorexpressedinCHOcells.Peptides 25, 2079-2086.
36. Langlet, C., Langer, I., Vertongen, P., Gaspard, N., Vanderwinden, J. M., andRobberecht, P. (2005). Contribution of the carboxyl terminus of the VPAC1 receptor to agonist-induced receptor phosphorylation, internalization, and recycling. J. Biol. Chem. 280, 28034-28043.
37. Larsson, L. I., Edvinsson, L., Fahrenkrug, J., Hakanson, R., Owman, C., Schaffalitzky de, M. O., et al. (1976). Immunohistochemical localization of a vasodilatory polypeptide (VIP) in cerebrovascular nerves. Brain Res. 113, 400-404.
38. Larsson, L. I., Fahrenkrug, J., Schaffalitzky de, M. O., Sundler, F., Hakanson, R., and Rehfeld, J. R. (1976). Localization of vasoactive intestinal polypeptide (VIP) to central and peripheral neurons. Proc. Natl. Acad. Sci. U.S.A. 73, 3197-3200.
39. Lutz, E. M., Sheward, W. J., West, K. M., Morrow, J. A., Fink, G., and Harmar, A.J. (1993).TheVIP2receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett. 334, 3-8.
40. MacKenzie, C. J., Lutz, E. M., Johnson, M. S., Robertson, D. N., Holland, P. J., and Mitchell, R. (2001). Mechanisms of phospholipase C activation by the vasoactive intestinal polypeptide/pituitary adenylatecyclase-activatingpolypeptidetype2receptor.Endocrinology 142, 1209-1217.
41. MacKenzie, C. J., Lutz, E. M., McCulloch, D. A., Mitchell, R., and Harmar, A. J. (1996). Phospholipase C activation by VIP1 and VIP2 receptors expressed in COS 7 cells involves a pertussis toxin-sensitive mechanism. Ann. N. Y. Acad. Sci. 805, 579-584.
42. Marie, J. C., Rouyer-Fessard, C., Couvineau, A., Nicole, P., Devaud, H., El Benna, J., et al. (2003). Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor. Mol. Pharmacol. 64, 1565-1574.
43. Maurice, P., Kamal, M., and Jockers, R. (2011). Asymmetry of GPCR oligomers supports their functional relevance. Trends Pharmacol. Sci. 32, 514-520.
44. McCulloch, D. A., Lutz, E. M., Johnson, M. S., MacKenzie, C. J., and Mitchell, R. (2000). Differential activation of phospholipase D by VPAC and PAC1 receptors. Ann. N. Y. Acad. Sci. 921, 175-185.
45. Milligan, G. (2009). G protein-coupled receptorhetero-dimerization:contribution to pharmacology and function. Br. J. Pharmacol. 158, 5-14.
46. Moody, T. W., Ito, T., Osefo, N., and Jensen, R. T. (2011). VIP and PACAP: recent insights into their functions/rolesinphysiologyanddisease from molecular and genetic studies. Curr. Opin. Endocrinol. Diabetes Obes. 18, 61-67.
47. Nachtergael, I., Gaspard, N., Langlet, C., Robberecht, P., and Langer, I. (2006). Asn229 in the third helix of VPAC1 receptor is essential for receptor activation but not for receptor phosphorylation and internalization: comparison with Asn216 in VPAC2 receptor. Cell. Signal. 18, 2121-2130.
48. Neumann, J.M., Couvineau, A., Murail, S., Lacapere, J. J., Jamin, N., and Laburthe, M. (2008). Class-B GPCR activation: is ligand helix-capping the key? Trends Biochem. Sci. 33, 314-319.
49. Pechon-Vallee, C., Magalon, K., Rasolonjanahary, R., Enjalbert, A., and Gerard, C. (2000). Vasoactive intestinal polypeptide and pituitary adenylatecyclase-activatingpolypeptides stimulate mitogen-activated proteinkinasein′th′epituitarycellline GH4C1 by a 3, 5 -cyclic adenosine monophosphate pathway. Neuroendocrinology 72, 46-56.
50. Perret, J., Vertongen, P., Solano, R. M., Langer, I., Cnudde, J., Robberecht, P., et al. (2002). Twotyrosine residues in the first transmembrane helixof thehumanvasoactiveintestinal peptide receptors play a role in supporting the active conformation. Br. J. Pharmacol. 136, 1042-1048.
51. Pierce, K. L., Premont, R. T., and Lefkowitz, R. J. (2002). Seventransmembrane receptors. Nat. Rev. Mol. Cell Biol. 3, 639-650.
52. Rasmussen, S. G., Choi, H. J., Rosenbaum, D. M., Kobilka, T. S., Thian, F. S., Edwards, P. C., et al. (2007). Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450, 383-387.
53. Rasmussen, S. G., Devree, B. T., Zou, Y., Kruse, A.C., Chung, K.Y., Kobilka, T. S., et al. (2011). Crystal structure of thebeta2adrenergicreceptor-Gsprotein complex. Nature 477, 549-555.
54. Reubi, J. C. (2000). In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann. N.Y. Acad. Sci. 921, 1-25.
55. Rosenbaum, D. M., Cherezov, V., Hanson, M. A., Rasmussen, S. G., Thian, F. S., Kobilka, T. S., et al. (2007). GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318, 1266-1273.
56. Rosenbaum, D. M., Rasmussen, S. G., and Kobilka, B. K. (2009). The structure and function of G-proteincoupled receptors. Nature 459, 356-363.
57. Rosenbaum, D. M., Zhang, C., Lyons, J. A., Holl, R., Aragao, D., Arlow, D. H., et al. (2011). Structure and functionof anirreversibleagonist-beta(2) adrenoceptor complex. Nature 469, 236-240.
58. Said, S.I., andMutt, V. (1970).Polypeptide with broad biological activity: isolationfromsmallintestine.Science 169, 1217-1218.
59. Said, S. I., and Rattan, S. (2004). The multiple mediators of neurogenic smooth muscle relaxation. Trends Endocrinol. Metab. 15, 189-191.
60. Shenoy, S. K., and Lefkowitz, R. J. (2011). beta-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol. Sci. 32, 521-533.
61. Shetzline, M. A., Walker, J. K., Valenzano, K. J., and Premont, R. T. (2002). Vasoactive intestinal polypeptide type-1 receptor regulation. Desensitization, phosphorylation, andsequestration.J.Biol.Chem. 277, 25519-25526.
62. Sheward, W. J., Lutz, E. M., and Harmar, A. J. (1995). The distribution of vasoactive intestinal peptide2 receptor messenger RNA in the rat brain and pituitary gland as assessed by in situ hybridization. Neuroscience 67, 409-418.
63. Spessert, R. (1993). Vasoactive intestinal peptide stimulation of cyclic guanosine monophosphate formation: further evidence for a role of nitric oxide synthase and cytosolic guanylate cyclase in rat pinealocytes. Endocrinology 132, 2513-2517.
64. Sreedharan, S. P., Patel, D. R., Huang, J. X., and Goetzl, E. J. (1993). Cloning and functional expression of a human neuroendocrine vasoactiveintestinalpeptidereceptor. Biochem.Biophys.Res.Commun.193, 546-553.
65. Sreedharan, S. P., Patel, D. R., Xia, M., Ichikawa, S., and Goetzl, E. J. (1994). Humanvasoactiveintestinalpeptide1 receptors expressed by stable transfectantscoupletotwodistinctsignaling pathways. Biochem. Biophys. Res. Commun. 203, 141-148.
66. Tams, J. W., Knudsen, S. M., and Fahrenkrug, J. (2001). Characterization of a G protein coupling "YL" motif of the human VPAC1 receptor, equivalenttothefirsttwoaminoacids in the"DRY"motif of the rhodopsin family. J. Mol. Neurosci. 17, 325-330.
67. Usdin, T. B., Bonner, T. I., and Mezey, E. (1994). Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135, 2662- 2680.
68. Vertongen, P., Solano, R. M., Perret, J., Langer, I., Robberecht, P., and Waelbroeck, M. (2001). Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix. Br. J. Pharmacol. 133, 1249-1254.
69. Wootten, D., Lindmark, H., Kadmiel, M., Willcockson, H., Caron, K. M., Barwell, J., et al. (2012). ReceptorActivityModifyingProteins (RAMPs) Interact with the VPAC(2) Receptor and CRF(1) Receptors and modulate their function. Br. J. Pharmacol. doi: 10.1111/j.14765381.2012.02202.x [Epub ahead of print].